Dawn Matthews is an invited speaker at the Leon Thal Summit to be held on June 5-6, 2025 at the Cleveland Clinic Lou Ruvo Center for Brain Health. She will present findings on the effects of repetitive head impact (RHI) on the brain in the first combination of data acquired in two major studies. The […]
ADMdx has successfully achieved the development objectives of its Phase II grant toward a diagnostic tool to detect and differentiate the effects of Repetitive Head Impact (RHI). RHI, incurred in contact sports, military blast, and other circumstances, can lead to significant clinical symptoms that in some cases transition to Chronic Traumatic Encephalopathy (CTE). This is […]
Dr. Pereira’s presentation, titled “Plasma p-tau217 in Alzheimer Disease Dementia relates to Glucose Metabolism in Specific Brain Regions”, will describe the results of collaborative analyses conducted by ADMdx on April 5 in Vienna, Austria. This work evaluated the relationship between plasma p-tau 217, which is a marker associated with amyloid and tau pathology found in […]
Dr. Brinton will present results from “Allopregnanolone Regenerative Therapeutic for Parkinson’s Disease: Open-Label Clinical Trial Preliminary Imaging Outcomes” at the 2025 AD/PD Conference in Vienna, Austria. This pilot study examined the effects of the naturally occurring neurosteroid allopregnanolone on brain tissue volume, dopamine transporters, and other brain health parameters in patients with Parkinson’s Disease using […]
ADMdx, in collaboration with Dr. Jeffrey Cummings, Dr. Jefferson Kinney, and other leading researchers has published work demonstrating relationships between blood biomarkers and brain imaging in patients with Alzheimer’s Disease. The publication, titled “Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in Alzheimer's disease patients” has been published in the July 9 […]
ADMdx’s CEO, Dawn Matthews, will be an invited panel speaker at the Alzheimer’s Drug Discovery Foundation (ADDF)’s upcoming Therapeutic Investigator Day on October 23, 2023. This symposium will be held in conjunction with the Clinical Trials for Alzheimer’s Disease (CTAD) conference in Boston, MA. Ms. Matthews’ talk will focus on the role of biomarkers in […]
The National Institutes of Aging (NIA) has approved the second year of funds for ADMdx’s $2 million Small Business Innovation Research grant. This work focuses on the development of a diagnostic product to detect the effects of Traumatic Brain Injury due to repetitive head impact and differentiate them from dementias such as Alzheimer’s disease. ADMdx […]
Dawn Matthews gave an invited presentation at the Society for Nuclear Medicine and Molecular Imaging (SNMMI), describing the Amyloid PET Profile developed by the Quantitative Imaging Biomarkers Alliance Amyloid PET working group. This Profile identifies sources of technical variability that can reduce the statistical power of measuring changes in amyloid in the brain. It provides […]
ADMdx is co-lead author with Cerveau Technologies on a newly published paper describing the results of a visual read method for the tau PET tracer MK-6240 manufactured by Cerveau. Tau is one of two abnormal proteins that are the basis for a diagnosis of Alzheimer’s disease, and the ability to measure it using a brain […]
The Radiological Society of North America (RSNA) Quantitative Imaging Biomarkers Alliance (QIBA) has established a working group to develop a Profile for the radiology and clinical trial community regarding the quantitative measurement of tau PET imaging. Tau, one of the two hallmark abnormal proteins in Alzheimer’s disease, can now be imaged in the living brain […]